FLT3 and acute myeloid leukemia: HiDAC was treated in 11 patients without mutation and only 1 patient with mutated CEBPA, therefore, we had no result on survival issue after HiDAC therapy in mutant NPM1 and FLT3-ITD AML (Table 3).